GlobalData on MSN1d
Gilead reports updated data from trial of acclaimed HIV PrEP drug
Gilead is looking towards approval of lenacapavir as HIV PrEP after reporting near-perfect efficacy in the PURPOSE-1 and ...
Queerty on MSN1d
More good news about the twice-yearly PrEP injection
Lenacapavir is already in use as a treatment for HIV. However, pharma giant Gilead has been testing it as an injectable form ...
India Today on MSN6d
Indian pharma firms sign deal to produce, sell generic HIV drug lenacapavir
Indian pharmaceutical companies are set to produce generic versions of lenacapavir, an HIV prevention drug, under agreements ...
The Pharma Letter2d
Efficacy and safety data show strong reduction in HIV infections with lenacapavir
US antivirals specialist Gilead Sciences has released additional data from its pivotal Phase III PURPOSE 2 trial providing an ...
Gilead Sciences : Phase 3 Data Shows 96% Reduction In HIV Infections With Lenacapavir
Gilead Sciences Inc. (GILD) announced that additional data from its pivotal Phase 3 PURPOSE 2 trial demonstrated a 96% reduction in ...
Managed Healthcare Executive5d
Gilead to Distribute Lenacapavir in Top HIV Countries, Critics Unhappy
The twice yearly lenacapavir injection will be available in 120 countries with a series of regulatory filings beginning by ...
BMJ2d
Gilead to license generic lenacapavir for HIV prophylaxis in 120 lower income countries
Ireland based pharmaceutical company Gilead Sciences has said it will grant licences to six generic manufacturers to produce low cost lenacapavir, which has shown unprecedented efficacy at preventing ...
BioSpace6d
Gilead Partners With Generics Developers to Provide HIV Drug to Low-Income Countries
Gilead Sciences is granting licenses to six companies to produce lenacapavir for pre-exposure prophylaxis, as well as for ...
Consider Buying Gilead To Benefit From Its Strong Outlook, Favorable Valuation
Discover why Gilead Sciences is a strong buy with potential blockbuster drugs in HIV and oncology, favorable valuation, and a ...
Devex1d
Devex Newswire: HIV prevention has game-changing tools, but access lags
Former U.K. foreign aid officials' advice to Prime Minister Keir Starmer. Plus time is running out for the U.N.'s “failing ...
unaids7d
UNAIDS response to Gilead’s announcement on signing voluntary licensing agreements on lenacapavir with six generic manufacturers
We welcome Gilead’s statement of commitment to non-profit pricing, but we had been waiting eagerly for a specific price. We ...
Indian pharma firms ink deal with U.S. drug maker Gilead to make, market generic HIV drug lenacapavir
Dr. Reddy's, Hetero, and Mylan partner with Gilead Sciences to manufacture generic lenacapavir for HIV prevention globally.